RECURSION PHARMACEUTICALS-A (RXRX) Stock Cash Flow
NASDAQ:RXRX - Nasdaq - US75629V1044 - Common Stock - Currency: USD
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -377.75M | -328.07M | -239.48M | -186.48M | -87.01M | |||
| Depreciation Amortization | 31.09M | 24.40M | 11.76M | 8.41M | 4.44M | |||
| Change In Working Capital | -55.32M | -50.26M | 104.92M | -310.00K | 30.83M | |||
| Interest Paid | N/A | 96.00K | 60.00K | 680.00K | 990.00K | |||
| Other non cash items | 84.15M | 66.14M | 39.28M | 19.77M | 6.33M | |||
| OPERATING CASH FLOW | -317.82M | -287.78M | -83.52M | -158.61M | -45.40M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -14.46M | -11.96M | -37.06M | -39.80M | -5.83M | |||
| Other Investing Activity | -3.42M | 1.73M | 230.31M | -231.95M | -2.91M | |||
| INVESTING CASH FLOW | -17.89M | -10.23M | 193.25M | -271.74M | -8.74M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -53.03M | -766.00K | -90.00K | -12.80M | 6.32M | |||
| Stock Issued/Repurchased | 427.17M | 140.90M | 154.44M | 471.34M | 239.81M | |||
| Other Financing Activity | N/A | N/A | N/A | 0.00 | 0.00 | |||
| FINANCING CASH FLOW | 374.14M | 140.13M | 154.35M | 458.54M | 246.14M | |||
| Exchange Rate Effect | 194.00K | 188.00K | -310.00K | N/A | N/A | |||
| CHANGE IN CASH | 38.63M | -157.69M | 263.77M | 28.19M | 192.00M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -317.82M | -287.78M | -83.52M | -158.61M | -45.40M | |||
| Capital Expenditure | -14.46M | -11.96M | -37.06M | -39.80M | -5.83M | |||
| FREE CASH FLOW | -332.29M | -299.73M | -120.58M | -198.41M | -51.23M | |||
All data in USD